

IN THE DRAWINGS

Authorization to amend sheet 1 of the drawings as shown in the attached Letter to the Chief Draftsperson is requested.

IN THE CLAIMS

Cancel claims 1-31, without prejudice.

Add the following claims:

--32. (new) A pharmaceutical composition comprising an antibody conjugated to a lipase able to lyse liposomes or a lipase component having no or less lipase activity in comparison to a corresponding lipase holoenzyme and, optionally a pharmaceutically acceptable carrier, diluent or excipient, said lipase component being selected from the group consisting of N-terminal recombinant CPAT and C-terminal recombinant CPAT.

33. (new) A pharmaceutical composition comprising a pharmaceutical agent protected in a liposome wherein the liposome is associated with or integrally contains a second lipase component able to reconstitute lipase activity when contacted with first lipase component bound to an antibody.

34. (new) A pharmaceutical package comprising in a first container a pharmaceutical composition comprising a composition comprising an antibody conjugated to a lipase able to lyse liposomes or a lipase component having no or less lipase activity in comparison to a corresponding lipase holoenzyme and, optionally a pharmaceutically acceptable carrier, diluent or excipient and, in a second container, a

composition comprising a pharmaceutical agent protected in a liposome which can be lysed by a lipase and, optionally, a pharmaceutically acceptable carrier, diluent or excipient.

Q² 35. (new) A pharmaceutical package comprising in a first container a pharmaceutical composition comprising a composition comprising an antibody conjugated to a lipase able to lyse liposomes or a lipase component having no or less lipase activity in comparison to a corresponding lipase holoenzyme and, optionally a pharmaceutically acceptable carrier, diluent or excipient and, in a second container, a composition of claim 33.

36. (new) A composition of claim 33 wherein at least one of said first lipase component or said second lipase component is N-terminal recombinant CPAT or C-terminal CPAT.

37. (new) A package of claim 34 wherein said lipase component is N-terminal recombinant CPAT or C-terminal CPAT.

38. (new) A package of claim 35 wherein said lipase component is N-terminal recombinant CPAT or C-terminal CPAT.--

REMARKS

Claims 1-31 have been canceled, without prejudice.

Claims 32-38 have been added.

An early and favorable Action on the merits is requested.